Recro Pharma Inc (NASDAQ:REPH) Given Consensus Rating of “Buy” by Brokerages
Shares of Recro Pharma Inc (NASDAQ:REPH) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $12.70.
REPH has been the topic of several research analyst reports. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Thursday, August 15th. ValuEngine raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. Oppenheimer set a $20.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, BidaskClub lowered shares of Recro Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 31st.
Several large investors have recently bought and sold shares of REPH. Russell Investments Group Ltd. bought a new position in shares of Recro Pharma during the 2nd quarter valued at about $48,000. Bessemer Group Inc. acquired a new position in shares of Recro Pharma in the second quarter worth about $57,000. Paloma Partners Management Co acquired a new position in shares of Recro Pharma in the second quarter worth about $109,000. Meeder Asset Management Inc. boosted its holdings in shares of Recro Pharma by 153.5% in the second quarter. Meeder Asset Management Inc. now owns 12,895 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 7,809 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in shares of Recro Pharma in the second quarter worth about $152,000. Institutional investors own 60.50% of the company’s stock.
Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The firm had revenue of $31.26 million for the quarter, compared to analysts’ expectations of $24.06 million. Recro Pharma had a negative net margin of 64.26% and a negative return on equity of 472.45%. Analysts anticipate that Recro Pharma will post -0.35 EPS for the current year.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: How do CD ladders protect against rising interest rates?
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.